ELIZABETH WILLMORE: Open Payments
NPI 1730788761 · RIVERTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,593 in 83 payments from 23 companies in 2025. Trend: 2023 $1,163 · 2024 $1,412 · 2025 $1,593
Food & beverage: $1,593
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $334 |
| AstraZeneca Pharmaceuticals LP | 7 | $148 |
| Corcept Therapeutics | 5 | $133 |
| Abbott Laboratories | 1 | $108 |
| Collegium Pharmaceutical, Inc. | 6 | $101 |
| Lilly USA, LLC | 5 | $85 |
| Amgen Inc. | 5 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Tris Pharma Inc | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 4 | $57 |
Products named: VRAYLAR, Korlym, FARXIGA, FREESTYLE LIBRE 3, Jornay PM, UBRELVY, CAPLYTA, MOUNJARO.
Industry payments across UT — which companies pay providers there.
